Chisholm 2005.

Methods	Single‐centre CCT conducted in the United Kingdom during the 2001‐2002 and 2002‐2003 influenza seasons
Participants	59 children with various non‐leukaemic malignancies who were receiving chemotherapy and 10 children with various non‐leukaemic malignancies who had been off chemotherapy for 4 weeks to 6 months. Age between 6 months and 16 years
Interventions	Trivalent inactivated split virion (Aventis Pasteur MSD) subcutaneously, with the following strains in 2001‐2002: A/New Cal/20/99 (H1N1), A/Panama/2007/99 (H3N2), B/Sichuan/379/99. In 2002‐2003, B/Hong Kong/331/01 replaced B/Sichuan/379/99 Age‐dependent schedule: < 4 years: two doses of 0.25 ml 3 to 4 weeks apart. 4 to 12 years: two doses of 0.5 ml 3 to 4 weeks apart. > 13 years: one dose of 0.5 ml. Previously immunised children: one dose 0.25 ml (< 4 years) or 0.5 ml (> 4 years)
Outcomes	(1) Seroconversion (defined as four‐fold rise in antibody titre) after vaccination (2) Development of protective HI titre (≥ 32) post‐vaccination (3) Pre‐ and post‐vaccination GMT (4) Adverse reactions
Notes	Results of children off chemotherapy stated only as "no impact" in subgroup analysis; no separate results were presented. Authors were contacted for additional information on the results of children off chemotherapy, and these results were obtained